Skip to content

Application of different doses of nalmefene pre-injection in painless gastrointestinal enddoscopy

Application of different doses of nalmefene pre-injection in painless gastrointestinal enddoscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088347
Enrollment
Unknown
Registered
2024-08-15
Start date
2024-08-20
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastroscopy

Interventions

Low dose nalmefene group:Pre injection of 0.1ug/kg nalmefene 2 minutes before anesthesia induction
Medium dose nalmefene group:Pre injection of 0.2ug/kg nalmefene 2 minutes before anesthesia induction
Physiological saline group:Pre injection of physiological saline 2 minutes before anesthesia induction

Sponsors

Taizhou Fourth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.ASA classification:I-II 2.Age:20-65 years old 3.BMI:18-25kg/m2 4.The patient and their family members are fully aware of and voluntarily cooperate with the anesthesia plan and study participation requirements for this examination.

Exclusion criteria

Exclusion criteria: 1.The patient has contraindications to anesthesia drugs; 2. During pregnancy or lactation; 3. Merge chronic systemic diseases; Drug users; 4. Individuals with mental disorders or neurological disorders

Design outcomes

Primary

MeasureTime frame
The incidence of respiratory depression in patients during painless examinations;

Secondary

MeasureTime frame
Wake up time;Vital signs at various time points;Respiratory rate;Satisfaction of patients and operating physicians;Adverse reactions;

Countries

China

Contacts

Public ContactXinghuoFu

Taizhou Fourth People's Hospital

15052402579@163.com+86 150 5240 2579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026